- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The chief executive of AlphaRx , Michael Lee, announced In a U.S. Securities and Exchange Commission filing, that he has concluded his purchase of 1,000,000 shares of his company for an average price of $0.17, increasing his holdings to about 11,327,866 shares or 13% of the company. Lee said following the purchase "I strongly believe that our share price is severely undervalued given the progress we have demonstrated in our Nanotechnology Drug Delivery Platform." 'Vansolin', Lee noted, intended for the treatment of noscomial pneumonia, is now on track to enter into human trials in 2008 and has a potential market value of US$3.6 billion. Lee concluded his comments by saying "we have four Nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars."
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Director, Market & Business Development
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016